Perspectives on Public Private Partnership: The R&D Based Vaccine Industry
AbstractPublic and private stakeholders, including the industrialized countries vaccine industry, have since its launch in 2000 been a member of the Global Alliance for Vaccines and Immunization (The GAVI Alliance), a public private partnership that strives to save children’s lives and protect people’s health by increasing access to immunization in the poorest countries of the world. This paper examines the R&D-based industry’s strategic intent and operational model, and contributions to innovation, supply and delivery of vaccines. Building on the World Health Organization’s (WHO) general concept of global access to medicines, the purpose is to provide insights into the commitments as well as challenges faced by the innovation-driven industry, and this in the following main areas: (i) The Quest for Global Health – Vaccines for the World; (ii) Availability – Innovation, Manufacturing and Supply; (iii) Affordability – Universal Access, Equity and Pricing; (iv) Adoption – Financing and Public Awareness; and (v) Alliances – Building a Strong Public Private Partnership.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Maastricht School of Management in its series Working Papers with number 2011/36.
Length: 55 pages
Date of creation: Nov 2011
Date of revision:
Find related papers by JEL classification:
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- O15 - Economic Development, Technological Change, and Growth - - Economic Development - - - Economic Development: Human Resources; Human Development; Income Distribution; Migration
This paper has been announced in the following NEP Reports:
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
- Daems, Rutger & Maes, Edith & Ramani, Shyama V., 2011. "Global Framework for Differential Pricing of Pharmaceuticals," MERIT Working Papers 054, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- David E. Bloom & David Canning & Mark Weston, 2005. "The Value of Vaccination," World Economics, World Economics, Economic & Financial Publishing, 1 Ivory Square, Plantation Wharf, London, United Kingdom, SW11 3UE, vol. 6(3), pages 15-39, July.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Maud de By).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.